Executive Summary: Top 25 Fastest Growing Tech Companies [2026]

  1. Kivu Bioscience – Next-Generation Antibody-Drug Coagulates
  2. Neolix – Level-4 Autonomous Vehicles
  3. Averna Therapeutics – Scalable Gene Insertion Modality
  4. Blossom App – Fixed-income Savings App
  5. Progentos Therapeutics – Small-Molecule Myelin Repair
  6. Neurosterix – Molecular Precision in Neuropsychiatry
  7. CETI AI – Decentralized AI Infrastructure
  8. Energy Storage Industries (ESI) – Iron-Flow Batteries
  9. SolidEdge Solution – Integrated Solid-State Batteries
  10. Crysalis Biosciences – Advanced Biorefineries for Low-Carbon Fuels
  11. Latus Bio – Adeno-Associated Virus Delivery Systems for Brain & Spinal Cord
  12. Fable Therapeutics – AI-driven Obesity Solutions
  13. Neysa – AI Acceleration Cloud System
  14. Abiologics – Chemically Synthesized Proteins with Programmable Designs
  15. Psivant Therapeutics – Physics-Based Platform for Small-Molecule Drug Design
  16. Valora Therapeutics – Molecules for Glycan-Targeted Immune Modulation
  17. Fugu Energy – Air Refinery Units for CO2 & Hydrogen Production
  18. Pavilion Solar – Premium Solar Carports
  19. Marea Therapeutics – Genetic Medicine for Cardiovascular Diseases
  20. Seaport Therapeutics – Liver-Bypassing Oral Delivery for Antidepressants & Anxiolytics
  21. SurrealDB – Unified Multi-Model Database
  22. CPTx – In-Vivo Cell Therapy
  23. SPOC Biosciences – Rapid Protein Production & Experiments
  24. SunGas Renewables – High-Temperature Gasification
  25. SleepRes – Inline Accessory & Algorithm for Respiratory Treatment

 

 

Frequently Asked Questions (FAQs)

1. What makes these tech companies stand out globally?

They combine breakthrough science or engineering with credible commercialization paths such as manufacturing scale, regulatory traction, or enterprise adoption, instead of relying on early-stage hype. Each is already influencing supply chains, funding patterns, or clinical pipelines.

2. Which regions are seeing the fastest momentum?

Asia-Pacific and North America are leading the pack. China and India dominate autonomous and clean-energy deployments, while the U.S. and U.K. are driving biotech and AI infrastructure innovation. Europe remains a critical hub for advanced manufacturing and sustainability solutions.

3. Why do these companies matter to investors and partners?

Each company represents a credible entry point into a fast-maturing frontier: next-generation therapeutics, data infrastructure, or sustainable energy. Partnering early offers access to proprietary platforms, supply chain influence, and first-mover advantages in markets that are likely to consolidate quickly over the next three to five years.

How We Selected the Top 25 Fastest-Growing Tech Companies

The data in this report comes from StartUs Insights’ Discovery Platform, covering over 9 million startups, scaleups, and tech companies globally.

  • We applied filters such as location, financials, technology readiness, and employee count to select 25 of the fastest-growing tech companies.
  • We further evaluated each company based on estimated revenue, total money raised, and proprietary innovation metrics that reflect their real-world growth within the global tech ecosystem.
  • Finally, we cross-checked this information with external sources for enhanced accuracy.

The final list combines established leaders shaping the global tech sector and highlights trends.

Explore the 25 Fastest Growing Tech Companies to Watch in 2026

1. Kivu Bioscience – Next-Generation Antibody-Drug Coagulates

Kivu Bioscience develops antibody-drug conjugates (ADCs) that deliver cancer drugs directly to tumor cells. The company uses a proprietary linker-payload system licensed from Synaffix to improve stability and reduce unwanted release of the drug.

This system attaches a targeted antibody to a chemotherapy payload through a controlled chemical linker. The technology aims to limit exposure to healthy tissue and support more predictable dosing. Kivu Bioscience advances several ADC candidates in solid tumor indications and works with contract manufacturers to prepare clinical-grade material.

The company closed a USD 92 million Series A led by Novo Holdings to push multiple oncology programs into the clinic, led by a team that includes veterans of first-wave ADC development.

2. Neolix – Level-4 Autonomous Vehicles

Neolix manufactures L4 autonomous EVs like the X6 and the supporting digital fleet stack to serve campuses, parks, industrial zones, and urban last-mile routes.

Its platform is vision-centric (multi-camera array with additional sensors) and paired with logistics-oriented applications such as centralized depot circulation and a 50-kilometer service radius.

Neolix’s EVs are equipped with 12 HD cameras and a LIDAR sensor to enable a 360-degree field of vision for a distance of up to 120 meters. Neolix operates a remote monitoring platform that displays location, battery level, and diagnostic alerts.

For municipalities and property owners, Neolix pitches safety certifications, remote ops, and monitoring dashboards to slot fleets into existing workflows.

In October 2025, Neolix secured a Series D funding round of over USD 600 million.

3. Averna Therapeutics – Scalable Gene Insertion Modality

Averna Therapeutics develops a gene-insertion platform that adds therapeutic DNA into cells through a standardized molecular design. The platform uses a familiar biologic format that supports stable expression and controlled insertion.

This design simplifies manufacturing steps that normally slow gene-therapy development. Averna tests the platform in multiple cell systems to assess accuracy, efficiency, and safety.

The company focuses on insertion challenges that limit the broader use of genetic medicines. This reduces the need for custom engineering for each new program.

Averna also builds production methods that maintain consistency at scale. These methods support controlled analytical testing, predictable formulation steps, and reliable delivery performance across different therapeutic models.

In June 2024, Averna Therapeutics secured a USD 82 million Series A round.

4. Blossom App – Fixed-Income Investment App

  • Founding Year: 2020
  • Location: Sydney, Australia
  • Notable news: Passed USD 75 million in Funds Under Management (FUM) in July 2024

Blossom provides a digital platform that connects retail savers to fixed-income investment products. The app links user accounts to a managed fund that allocates capital across government bonds, corporate bonds, and mortgage-backed securities.

The interface displays daily earnings and updates account balances through internal reporting tools. Blossom also supports recurring deposits and transparent withdrawal rules that match each product type.

The platform simplifies bond exposure for users who do not manage portfolios directly. It centralizes portfolio oversight, risk controls, and regulatory compliance through a single management structure. This structure handles custody, fund administration, and investor reporting.

In July 2024, Blossom passed a USD 75 million milestone in managed funds.

5. Progentos Therapeutics – Small-Molecule Myelin Repair

Progentos Therapeutics develops small-molecule drugs that support the repair of myelin, the protective layer around nerve fibers that becomes damaged in multiple sclerosis.

The company identifies biological signals that enable immature support cells to mature into myelin-forming cells. These mature cells then rebuild the damaged insulation around nerves.

Progentos tests its compounds in models that measure how well new myelin forms. The team uses imaging methods, electrical-signal recordings, and tissue analysis to track changes in nerve health. This allows the company to compare drug candidates and understand which ones support the strongest repair activity.

Progentos Therapeutics secured USD 65 million in Series A funding in 2024.

6. Neurosterix – Molecular Precision in Neuropsychiatry

  • Founding Year: 2024
  • Location: Geneva, Switzerland
  • Revenue: Launched with USD 63 million in initial funding

Neurosterix develops small-molecule drugs that adjust how brain receptors respond to natural signals. These drugs bind to secondary sites on the receptor, which are separate from the main active site. This method gives more precise control of brain activity than direct receptor activation. It also reduces unwanted effects that can occur with broader-acting medicines.

The company studies how each molecule influences pathways involved in mood, perception, and cognition. Neurosterix measures safety, receptor selectivity, and changes in behavior in controlled models.

It then refines compounds that show stable and targeted effects. This process supports the development of treatments for psychiatric and neurological conditions that require accurate pathway modulation.

Neurosterix secured a USD 63 million investment upon launch in April 2024.

7. CETI AI – Decentralized AI Infrastructure

  • Founding Year: 2024
  • Location: London, UK
  • Funding: Received USD 60 million in funding from BCII Enterprises in 2024

CETI AI is assembling a decentralized, globally distributed AI infrastructure that connects workload demand to heterogeneous compute supply via its Intelligent Compute Fabric (ICF).

The fabric assigns tasks to available machines and coordinates them through a secure control layer. This structure allows organizations to use dispersed GPU resources as a single pool without exposing internal hardware details.

The platform includes tools for model training, data transfer, and workload monitoring. It tracks performance, resource use, and job completion across all connected nodes.

CETI AI designs the fabric to support teams that need flexible and scalable compute access across different locations. The system reduces manual setup and creates a unified environment for running large AI tasks.

CETI AI has secured USD 60 million in funding in 2024.

8. Energy Storage Industries (ESI) – Iron-Flow Batteries

  • Founding Year: 2020
  • Location: Paddington, Australia
  • Funding: USD 40 million in combined public and private funding in 2024
  • Notable news: announced partnership with Sharp Corporation to develop zinc-air flow battery technology

Energy Storage Industries (ESI) produces iron-flow batteries that store electricity using iron, salt, and water. The system moves these materials between two tanks and a reaction cell to charge and discharge energy.

This chemistry avoids flammable components and supports frequent cycling without significant performance loss. It also maintains stable output during long discharge periods, which benefits grids with high renewable use.

ESI supplies containerized units for smaller sites and larger Energy Centre installations for utility projects. These systems operate with pumps, pipes, and a control system that manages flow rates and electrical output.

In 2024, ESI secured a combined amount of AUD 64 million (USD 40 million) in private and government funding. It is currently constructing a manufacturing facility in Queensland, Australia, backed by a USD 65M investment.

9. SolidEdge Solution – Integrated Solid-State Batteries

  • Founding Year: 2021
  • Location: Hsinchu, Taiwan
  • Notable News: 97% of shares acquired by Hyield Venture Capital at USD 1.2 million in 2024

SolidEdge Solution develops solid-state lithium battery cells and the materials that support them. Solid-state batteries replace the liquid electrolyte in conventional lithium-ion cells with a solid layer.

This design reduces leakage risk and improves thermal stability. SolidEdge manufactures solid electrolytes, cathodes, anodes, and integrated cell stacks that operate together as a complete system.

The company produces battery modules that support custom shapes and energy requirements. Each module includes a solid electrolyte layer, engineered electrode materials, and a pressure-managed housing that keeps the layers in contact.

SolidEdge tests cell performance for durability, charge cycles, and temperature tolerance. These evaluations help the team match specific material combinations to applications in electric vehicles, consumer devices, and industrial equipment.

In 2024, 97% of SolidEdge’s shares were acquired at an estimated value of USD 1.2 million.

10. Crysalis Biosciences – Advanced Biorefineries for Low-Carbon Fuels

  • Founding Year: 2022
  • Location: Sauget, IL, USA
  • Notable news: Announced to open a USD 239.5 million sustainable aviation fuel plant in Illinois

Crysalis Biosciences develops biorefinery systems that convert biomass into low-carbon ethanol, protein coproducts, and purified industrial solvents. The process uses fermentation to break down plant material and separation steps to isolate each product stream.

The company also captures biogenic CO2 that forms during fermentation. This CO2 supports downstream uses such as fuel production or industrial processing.

Crysalis refurbishes existing industrial sites and adapts them to modern biorefinery operations. Each site includes fermentation tanks, distillation columns, and treatment units that handle biomass inputs and final outputs.

The company designs its workflow to improve energy efficiency and reduce waste. This structure supports local supply chains for renewable fuels and chemical ingredients.

Crysalis Biosciences announced the development of USD 239.5 million facility in Illionis.

11. Latus Bio – Adeno-Associated Virus Delivery Systems for Brain & Spinal Cord

Latus Bio develops adeno-associated virus (AAV) capsids for targeted delivery into the brain and spinal cord. The company screens millions of capsid variants directly in non-human primates to identify versions that reach specific regions of the central nervous system.

This measures how well each capsid enters neurons or support cells and how long it maintains expression. The result is precise drug delivery with lower required doses.

The platform studies how different routes of administration affect tissue uptake. These routes include intrathecal dosing, which introduces the vector into the spinal fluid, and intravenous dosing, which circulates the vector through the bloodstream.

Latus evaluates each capsid for safety, distribution, and manufacturability. The company organizes these data into discovery pipelines that support gene-therapy programs requiring selective central nervous system targeting.

Latus secured USD 54 million in Series A funding in 2024.

12. Fable Therapeutics – AI-driven Obesity Solutions

  • Founding Year: 2022
  • Location: Boston, MA, USA
  • Funding: Raised USD 53.5 million in 2024

Fable Therapeutics designs biologic drug candidates using machine-learning models and protein-engineering tools. The platform analyzes large datasets of protein sequences and structures to predict stable and active molecules.

These predictions guide the construction of new proteins that interact with specific biological targets. Fable focuses on metabolic diseases such as obesity that require long-acting and precisely tuned biologic activity.

The company evaluates each molecule in laboratory systems that measure potency, durability, and manufacturing feasibility. These tests include cell-based assays and animal studies that track how proteins move through the body.

Fable refines promising candidates through repeated design cycles. This process supports the development of biologics with controlled behavior and predictable therapeutic profiles.

In 2024, Fable raised USD 53.5 million in Seed and Series A funding to carry the company into 2026.

13. Neysa – AI Acceleration Cloud System

  • Founding Year: 2023
  • Location: Mumbai, India
  • Funding: Received a combined amount of USD 50 million in Seed and Series A funding

Neysa develops Neysa Velocis, an AI cloud system that unifies model training, fine-tuning, deployment, and monitoring under a single dashboard.

It features AI Platform-as-a-Service capabilities and segment-specific solutions for banking and fintech, as well as e-commerce and research.

The system includes controls for user access, security, and workspace management. These controls help organizations handle sensitive data across different projects.

The platform also supports large-scale workloads by coordinating compute resources across cloud environments. Neysa presents these functions in a format that focuses on clear metrics, structured pipelines, and maintainable operations.

Neysa completed Seed and Series A funding rounds in 2024, securing a combined investment of USD 50 million.

 

 

14. Abiologics – Chemically Synthesized Proteins with Programmable Designs

  • Founding Year: 2021
  • Location: Cambridge, MA, US
  • Revenue: Received USD 50 million in funding from Flagship Pioneering

Abiologics creates protein-like medicines through chemical synthesis rather than biological production. The company uses generative models to design molecules with specific shapes and functions.

These molecules include non-natural building blocks that expand the range of possible structures beyond standard amino acids. This approach supports the design of proteins with controlled stability, binding behavior, and therapeutic activity.

The platform combines automated synthesis tools with laboratory tests that measure how each molecule behaves in cells and tissues. These tests examine potency, durability, and movement through the body.

Abiologics selects candidates that show consistent performance in controlled studies. The company organizes these results into discovery pipelines for immune, metabolic, and oncology applications.

Abiologics’ launch in 2024 was backed by a USD 50 million investment from Flagship Pioneering.

15. Psivant Therapeutics – Physics-Based Platform for Small-Molecule Drug Design

Psivant Therapeutics designs small-molecule drugs using a physics-based QUASAIR platform. The platform models molecular interactions with quantum and classical calculations to predict how a compound binds to its target.

It combines these simulations with structural biology and medicinal chemistry to refine each molecule. The company focuses on immunology and inflammation targets that require high selectivity and consistent activity across multiple biological systems. It evaluates drug candidates through assays that measure binding strength, functional effects, and safety profiles.

In January 2025, Psivant Therapeutics announced a partnership with Acellera Therapeutics for collaborative development of drug discovery based on AI and Quantum Computing.

16. Valora Therapeutics – Molecules for Glycan-Targeted Immune Modulation

  • Founding Year: 2023
  • Location: La Jolla, California, US
  • Revenue: Raised USD 30 million in Seed funding in 2024

Valora Therapeutics develops AbLec molecules, which combine antibody and lectin components to recognize specific glycan patterns on cells. Glycans are sugar structures that influence how immune cells communicate and respond to their environment.

AbLec constructs bind to these patterns and adjust immune activity with greater precision than standard antibodies. This approach targets pathways involved in immune regulation, cancer biology, and inflammatory responses.

Valora evaluates each AbLec molecule through assays that measure binding behavior, receptor activation, and functional immune effects. The company also tests manufacturability and structural stability to ensure consistent performance. This work supports programs that require controlled modulation of glycan-driven immune interactions.

The company raised USD 30 million in a 2024 Seed round.

17. Fugu Energy – Air Refinery Units for CO2 & Hydrogen Production

  • Founding Year: 2023
  • Location: Austin, TX, USA
  • Revenue: Raised USD 1-1.7 million in Seed funding

Fugu Energy builds AirRefinery modular units that produce carbon dioxide and hydrogen using solar power and water. Each unit uses electrochemical processes to separate gases from air and water inside a containerized structure.

The system then feeds these gases into catalytic equipment that forms green methanol. This design supports operation in remote or high-solar regions without reliance on grid electricity. Fugu combines the AirRefinery modules with site layouts that coordinate solar input, water supply, and gas-handling equipment.

The company evaluates gas purity, energy efficiency, and methanol output through controlled tests. These evaluations guide the configuration of larger sites that use multiple AirRefinery units to increase production capacity.

The company raised an estimated USD 1-1.7 million in Seed funding.

18. Pavilion Solar – Premium Solar Carports

  • Founding Year: 2023
  • Location: Miami, FL, USA
  • Funding: USD 100,000 grant from the US Department of Energy

Pavilion Solar develops EnPod, a solar carport system that generates electricity through integrated photovoltaic panels. The structure provides covered outdoor space while producing power for homes, vehicles, or small commercial sites.

EnPod uses a steel frame, weather-resistant materials, and electrical components that route solar energy to an inverter or storage system. The design supports properties that cannot install rooftop panels or need additional solar capacity on open ground.

Pavilion Solar’s solution was awarded a USD 100,000 grant from the US Department of Energy in 2024.

19. Marea Therapeutics – Genetic Medicine for Cardiovascular Diseases

  • Founding Year: 2022
  • Location: San Francisco, CA, USA
  • Funding: Raised USD 190 million in combined Series A and B funding

Marea Therapeutics develops drugs that target hormone pathways controlled by adipose tissue. These pathways influence lipid handling, inflammation, and other factors linked to cardiometabolic disease.

The company’s lead program, MAR001, modulates a specific adipose-derived signal that affects cardiovascular risk markers. Marea studies how this pathway changes in people with metabolic disorders and uses these findings to guide dose selection and patient characterization.

The company evaluates each drug candidate through clinical and laboratory tests that measure hormone activity, lipid levels, and inflammatory markers. These tests help determine how the drug affects metabolic pathways that contribute to cardiovascular disease.

Marea organizes these data into development plans that focus on well-defined biological mechanisms and measurable treatment effects.

Marea secured a combined funding of USD 190 million in Series A and B rounds in 2024.

20. Seaport Therapeutics – Liver-Bypassing Oral Delivery for Antidepressants & Anxiolytics

  • Founding Year: 2020
  • Location: Boston, MA, USA
  • Funding: Raised USD 225 million in Series B funding

Seaport Therapeutics develops the Glyph platform, which helps small-molecule drugs enter the lymphatic system after oral dosing. Glyph attaches a lipid-based structure to a drug molecule.

This structure moves the drug into lymphatic vessels instead of the liver, which allows more of

the active compound to reach the bloodstream unchanged. This supports oral delivery for compounds that normally break down during digestion or first-pass metabolism.

 

 

The company focuses on antidepressant and anxiolytic compounds that benefit from consistent blood levels. These programs study how improved oral absorption affects symptom control in mood and anxiety disorders.

Seaport Therapeutics evaluates each candidate through studies that measure absorption, lymphatic transport, and safety. These data help the team compare different chemical designs and identify versions that maintain consistent exposure with standard oral capsules.

Seaport Therapeutics’ solution secured USD 225 million in Series B funding in 2024.

21. SurrealDB – Unified Multi-Model Database

  • Founding Year: 2022
  • Location: London, UK
  • Funding: Raised USD 20 million in Series A funding

SurrealDB combines document, graph, relational, time-series, vector search, and geospatial models under one engine with an SQL-like query language, SurrealQL. The platform is cloud-native and horizontally scalable, with a proprietary companion GUI Surrealist, and enterprise security attestations.

The platform includes real-time transactions, user authentication, and horizontal scaling features. It also offers Surrealist, a visual interface that helps users test queries and explore data structures. SurrealDB runs on a variety of environments, including cloud systems and local servers. This provides consistent data behavior across development and production settings.

SurrealDB secured a USD 20 million funding round in 2024.

22. CPTx – In-Vivo Cell Therapy

  • Founding Year: 2021
  • Location: Planegg, Germany
  • Funding: Raised USD 30 million in Series B funding

CPTx develops genetic medicines that create therapeutic cell functions directly inside the body. The platform uses single-stranded DNA templates that carry genetic instructions for specific immune cell changes.

These templates pair with targeted lipid nanoparticles that deliver the DNA to selected cell types. The approach avoids viral vectors and supports controlled expression through a programmable DNA structure.

The company evaluates how different ssDNA designs influence stability, expression levels, and cell behavior. It also studies how targeted lipid nanoparticles distribute DNA and enter immune cells.

CPTx tests each combination through assays that measure protein production, cell activation, and safety. This work supports programs that require direct modification of immune cells within the body.

The company secured USD 30 million in Series B funding in 2024.

23. SPOC Biosciences – Rapid Protein Production & Experiments

  • Founding Year: 2018
  • Location: Scottsdale, AZ, USA
  • Funding: Raised ~USD 19 million from angel investors & 7.5 million in federal grants.

SPOC Biosciences develops proteomic chips that create and test thousands of proteins in a single experiment. Each chip uses a cell-free system that synthesizes proteins directly on its surface without the need for live cells.

The platform produces between 10 and 30 thousand distinct proteins per run and measures how each protein binds to drug candidates. These measurements include binding strength, binding speed, and other kinetic features that help characterize early drug interactions.

The system completes this process in hours instead of the weeks required for traditional protein production and testing. SPOC collects the data through automated imaging and signal-detection tools built into the chip workflow.

The company uses these datasets to compare drug molecules and identify promising interactions at an early research stage. This structure supports drug discovery teams that need rapid assessment of large protein sets.

SPOC Biosciences has attracted around USD 19 million from angel investors and 7.5 million in federal grants.

24. SunGas Renewables – High-Temperature Gasification

SunGas Renewables develops the S1000 system, which converts biomass into synthesis gas through high-temperature gasification. The system uses controlled heat and pressure to break down wood residues and other organic feedstocks into a gas mixture of hydrogen and carbon monoxide.

This gas supports the production of methanol, hydrogen, and sustainable aviation fuel. The S1000 includes feed-handling equipment, a gasifier, filtration units, and a control system that manages temperature and airflow.

The company supplies engineering packages that outline how to design and operate full-scale facilities around the S1000. These packages cover material flows, energy inputs, and gas-cleanup requirements for different project sizes.

SunGas Renewables is engaged in a USD 2+ billion project along with C2X, ENEOS, and Johnson Matthey to launch a bioethanol plant in Louisiana.

25. SleepRes – Inline Accessory & Algorithm for Respiratory Treatment

  • Founding Year: 2022
  • Location: Nashville, TN, USA

SleepRes builds hardware and algorithms to improve positive airway pressure (PAP) therapy adherence for sleep apnea patients. Its V̇-Com is an FDA-cleared inline accessory that softens peak inspiratory flow, making existing respiratory treatments more tolerable for the affected patients.

SleepRes also develops Kairos Positive Airway Pressure (KPAP), an investigational pressure-timing algorithm that delivers optimal air pressure at key moments of the breathing cycle.

The company has published randomized data demonstrating non-inferiority in efficacy against standard CPAP with superior comfort.

Discover all the Fastest Growing Tech Companies to Stay Ahead

With record funding rounds, expanding manufacturing capacity, and new breakthroughs across AI, biotechnology, and clean energy, the fastest-growing tech companies in this report demonstrate how innovation converts into measurable global impact.

These rapidly scaling innovators show how deep-tech R&D, scalable business models, and cross-sector partnerships can turn emerging science into real commercial success, setting the pace for what defines the fastest-growing technology company in the world today.

With access to over 9 million emerging companies and 20K+ technologies & trends globally, our AI and Big Data-powered Discovery Platform equips you with the actionable insights you need to stay ahead of the curve in your market.

Leverage this powerful tool to spot the next big thing before it goes mainstream. Stay relevant, resilient, and ready for what is next.